MTX-101 · Phase 2b-ready
A once-daily tablet for the migraine patients CGRP therapy leaves behind
MTX-101 is a sublingual tablet that works outside the CGRP pathway. It is repurposed from an approved medicine and has an FDA-agreed Phase 2b design in chronic migraine. Manistee is seeking an acquirer or development partner.
- Stage
- Phase 2b-ready, FDA-agreed design
- Indication
- Chronic migraine prevention
- Format
- Once-daily sublingual tablet
- Regulatory path
- Potential 505(b)(2)
- Intellectual property
- Issued method-of-use patent
Migraine prevention has one dominant mechanism, and it doesn't work for everyone
Every branded migraine preventive approved since 2018 targets CGRP. Patients who don't respond, or who stop because of injections and infusions, have few places to go.
~3.5M
Americans live with chronic migraine, 15 or more headache days a month. Only about 500,000 are treated.
~1 in 3
CGRP-treated patients never reach a 50% reduction in migraine days, even when they take their medicine.
<30%
of patients are still taking an oral preventive after six months.
The only oral preventive in development outside CGRP
Lundbeck's PACAP antibody, bocunebart, reported positive Phase 2b data in June 2026. It is given by infusion or injection. MTX-101 would be the oral alternative outside CGRP.
See the competitive landscape- A different mechanismTargets a different receptor and modulates the effects of both CGRP and PACAP.
- A known safety heritageRepurposed from an approved ophthalmic medicine with a characterized systemic profile.
- A defined pathFDA-agreed Phase 2b design in chronic migraine, with a US launch targeted for 2033.
A team that has built and sold companies, advised by the field's leading migraine researchers
Meet the teamRobert Bratzler, PhD
Co-founder and COO. Helped build four healthcare companies from inception to NASDAQ IPO, including Sepracor.
Mahan Chehrenama, DO
CMO. Neurologist and headache specialist; previously at Amgen, Revance and Avanir.
Marcelo Bigal, MD, PhD
Advisor. As CMO and CSO of Teva, led development of the migraine antibody Ajovy.
Richard Lipton, MD
Advisor. Directs the Montefiore Headache Center; past president of the American Headache Society.
Evaluating MTX-101?
Clinical data, mechanism detail and the development plan are available to qualified parties under a confidentiality agreement.